Literature DB >> 2859879

Brief review of published alprazolam clinical studies.

R N Straw.   

Abstract

The clinical efficacy of alprazolam has been evaluated in both anxiety states and depressive disorders. In anxiety neurosis, studies have been conducted vs placebo and/or other benzodiazepine tranquilizers. Reports, to date, with regard to panic/phobia disorders have been limited to open-label studies and a single report from a placebo-controlled study. In depression, both open-label and double-blind studies (vs tricyclic antidepressants) have been published.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859879      PMCID: PMC1463502          DOI: 10.1111/j.1365-2125.1985.tb02743.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Diagnostic criteria for use in psychiatric research.

Authors:  J P Feighner; E Robins; S B Guze; R A Woodruff; G Winokur; R Munoz
Journal:  Arch Gen Psychiatry       Date:  1972-01

2.  Alprazolam in the treatment of generalized anxiety and panic disorders: a double-blind placebo-controlled study.

Authors:  G Chouinard; L Annable; R Fontaine; L Solyom
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

3.  A controlled clinical trial of alprazolam for the treatment of anxiety.

Authors:  K Rickels; I Csanalosi; P Greisman; D Cohen; J Werblowsky; H A Ross; H Harris
Journal:  Am J Psychiatry       Date:  1983-01       Impact factor: 18.112

4.  [Clinical comparison between alprazolam and lorazepam. A polycentric study in double blind].

Authors:  L Botte; J Bienfait; J Dethier; P Even; J L Evrard; J Fraipont; L Goffin; P Willemse
Journal:  Acta Psychiatr Belg       Date:  1981 Nov-Dec

5.  Multicenter double-blind efficacy and safety study comparing alprazolam, diazepam and placebo in clinically anxious patients.

Authors:  J B Cohn
Journal:  J Clin Psychiatry       Date:  1981-09       Impact factor: 4.384

6.  Double-blind clinical assessment of alprazolam, a new benzodiazepine derivative, in the treatment of moderate to severe anxiety.

Authors:  K C Greiss; R Fogari
Journal:  J Clin Pharmacol       Date:  1980 Nov-Dec       Impact factor: 3.126

7.  Alprazolam in bipolar-I depressions.

Authors:  A J Rush; M A Schlesser; M Erman; C Fairchild
Journal:  Pharmacotherapy       Date:  1984 Jan-Feb       Impact factor: 4.705

8.  Alprazolam in clinically anxious patients with depressed mood.

Authors:  G C Aden
Journal:  J Clin Psychiatry       Date:  1983-01       Impact factor: 4.384

9.  Anxiolytic efficacy of alprazolam compared to diazepam and placebo.

Authors:  B M Maletzky
Journal:  J Int Med Res       Date:  1980       Impact factor: 1.671

10.  Alprazolam compared to diazepam and placebo in the treatment of anxiety.

Authors:  G C Aden; S G Thein
Journal:  J Clin Psychiatry       Date:  1980-07       Impact factor: 4.384

View more
  1 in total

Review 1.  Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence.

Authors:  Aristeidis Chaidos; Valentina Caputo; Anastasios Karadimitris
Journal:  Ther Adv Hematol       Date:  2015-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.